Amgen Inc
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen Biosimilars Included in Other Product Sales by Year
Biosimilars Included in Other Product Sales — Worldwide ($M) ($M)
Amgen Biosimilars Included in Other Product Sales: $683M in FY2025, down 5.8% from a year earlier.
Where the FY2025 figure comes from
“|| (2) Other products consist of Aimovig ® , AVSOLA ® , KANJINTI ® , EPOGEN ® , RIABNI ® , BKEMV ® /BEKEMV ™ , IMLYGIC ® , NEUPOGEN ® , Corlanor ® , RAYOS ® , DUEXIS ® , VIMOVO ® , Sensipar ® /Mimpara ™ , and PENNSAID ® , where Biosimilars total $683 million in FY ’25 and $667 million in FY ’24.”
Source: Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗
Reported in Form 10-Q / 10-K MD&A Other Product Sales by Geographic Region Footnote.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Biosimilars Included in Other Product Sales — Worldwide ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 683 | -5.8% | Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 725 | +119.0% | Form 8-K (amgn-20241231earningsrelea.htm, filed 2025-02-04) ↗ |
| FY2023 | Dec 31, 2023 | 331 | +114.9% | Form 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗ |
| FY2022 | Dec 31, 2022 | 154 | – | Form 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗ |
Cite this data
StockData. (2026). Amgen Biosimilars Included in Other Product Sales ($M), annual FY2022–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-biosim-in-other-ww
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.